This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Henry Schein (HSIC) Down 2.5% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Hold on to Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) on favorable international Dental business trends and bullish guidance.
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Henry Schein (HSIC) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Robust performances by all three operating segments drove Henry Schein's (HSIC) first-quarter 2022 revenues.
Henry Schein (HSIC) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 7.44% and 1.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 12.77% and 4.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Robust demand in the global dental market with the steady improvement in patient traffic is likely to have contributed to Henry Schein's (HSIC) Q1 performance.
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Catalent's (CTLT) Latest Manufacturing Suites to Boost Capacity
by Zacks Equity Research
Catalent's (CTLT) latest site expansion is expected to significantly boost its business.
Henry Schein (HSIC) Stock Moves Up 20.6%: What's Driving It?
by Zacks Equity Research
Henry Schein's (HSIC) stock rallied on strong fourth-quarter performance and bullish 2022 EPS guidance.
Here's Why You Should Retain Zimmer Biomet (ZBH) Stock For Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) given robust demand for its ROSA robotics line and continued investment in profitable business areas.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Here's Why You Should Hold on to Haemonetics (HAE) For Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.
DexCom (DXCM) G6 CGM System Now Available to TRICARE Members
by Zacks Equity Research
The availability of DexCom's (DXCM) G6 CGM System to diabetic TRICARE military members is expected to enable them to make better real-time decisions about their health.
Fresenius Medical (FMS) Launches Campaign to Boost Kidney Care
by Zacks Equity Research
Fresenius Medical's (FMS) My Reason campaign will help scientists understand genetic variations in patients with chronic kidney disease in a better way.
Here's Why You Should Retain Phibro (PAHC) Stock For Now
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC) owing to the robust performances by its Animal Health and Mineral Health segments.
The Zacks Analyst Blog Highlights Splunk, Vertex Pharmaceuticals, Henry Schein, Jack Henry & Associates, and Check Point Software Technologies
by Zacks Equity Research
Splunk, Vertex Pharmaceuticals, Henry Schein, Jack Henry & Associates, and Check Point Software Technologies are part of Top Analyst Blog.
Integer Holdings' (ITGR) Latest Buyout to Expand Its Footprint
by Zacks Equity Research
Integer Holdings' (ITGR) buyout of Aran Biomedical is set to expand its presence in high-growth markets as well as enhance its product offerings.
Masimo's (MASI) Sound United Buyout to Boost Product Portfolio
by Zacks Equity Research
Masimo's (MASI) completion of Sound United's buyout to help enhance the former's extended portfolio of hospital and home medical technology solutions.
Top 5 High-Flying Nasdaq Stocks Amid Index's YTD Meltdown
by Nalak Das
We have narrowed our search to five Nasdaq listed stocks that have witnessed double-digit rally year to date. These are: VRTX, SPLK, HSIC, CHKP and JKHY.
Merit Medical's (MMSI) SCOUT Bx Delivery System Gets FDA Nod
by Zacks Equity Research
Merit Medical's (MMSI) receipt of FDA clearance for the SCOUT Bx system can streamline treatment for cancer patients.
Quidel Corporation (QDEL) Reports Solid Preliminary Q1 Revenues
by Zacks Equity Research
Quidel's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued robust sales of its SARS-related products.
Abiomed (ABMD) Announces Successful Usage of Impella in Japan
by Zacks Equity Research
Continued adoption of Abiomed's (ABMD) Impella 5.5 with SmartAssist is likely to provide a minimally invasive surgical option for acute heart failure patients.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.